glyburide Side Effects
Also known as: DiaBeta, Glynase
Analysis of 23,902 adverse event reports submitted to the FDA from 2003 to 2025.
Total Reports
23,902
Death-Related
2,123
8.9% of reports
Hospitalizations
8,393
35.1% of reports
Top Indication
Diabetes Mellitus
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 2,123 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 549 |
| RENAL FAILURE | 207 |
| MYOCARDIAL INFARCTION | 199 |
| CARDIAC ARREST | 152 |
| DYSPNOEA | 151 |
| PNEUMONIA | 145 |
| CARDIAC FAILURE CONGESTIVE | 144 |
| COMPLETED SUICIDE | 140 |
| PAIN | 109 |
| RESPIRATORY FAILURE | 101 |
| ANAEMIA | 98 |
| HYPOTENSION | 96 |
| SEPSIS | 93 |
| ANXIETY | 92 |
| VOMITING | 89 |
| RENAL FAILURE ACUTE | 88 |
| CARDIO-RESPIRATORY ARREST | 86 |
| DIARRHOEA | 86 |
| ASTHENIA | 84 |
| CORONARY ARTERY DISEASE | 84 |
Reactions in Hospitalization Reports
Top reactions in 8,393 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| HYPOGLYCAEMIA | 754 |
| MYOCARDIAL INFARCTION | 720 |
| DYSPNOEA | 623 |
| CARDIAC FAILURE CONGESTIVE | 604 |
| NAUSEA | 568 |
| BLOOD GLUCOSE INCREASED | 566 |
| ASTHENIA | 564 |
| PNEUMONIA | 507 |
| FALL | 454 |
| DIZZINESS | 449 |
| VOMITING | 445 |
| DIARRHOEA | 443 |
| WEIGHT DECREASED | 426 |
| PAIN | 417 |
| RENAL FAILURE | 413 |
| FATIGUE | 408 |
| CEREBROVASCULAR ACCIDENT | 406 |
| CHEST PAIN | 399 |
| CORONARY ARTERY DISEASE | 360 |
| ANAEMIA | 348 |
Nearby — Related Medications
What the FAERS Data Reveals About glyburide Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 23,902 voluntary reports linked to glyburide and its brand equivalents (DiaBeta, Glynase), spanning 2003 through 2025. Of those, 2,123 (8.9%) listed death as an outcome and 8,393 (35.1%) involved hospitalization. The most common indication reported alongside adverse events was Diabetes Mellitus.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 48% were female and 52% male; age distribution skews toward 45-64, with 6,844 reports in that bracket. The single most reported reaction is blood glucose increased with 3,038 submissions, followed by nausea and weight decreased.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.